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KEY POINT 
 
Regionally localized PD-L1+ macrophages form a specialized microenvironmental niche for 
Hodgkin Reed-Sternberg cells in cHL.  50 
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ABSTRACT 
 
Signaling between programmed cell death protein 1 (PD-1) and the programmed cell death -55 
1 ligands (PD-1 ligands, PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg 
(HRS) cells to evade anti-tumor immunity in classical Hodgkin lymphoma (cHL).  Copy 
number alterations of 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) contribute to robust PD-L1 
and PD-L2 expression by HRS cells.  PD-L1 is also expressed by non-malignant tumor-
associated macrophages (TAMs) but the relationships between PD-L1+ HRS cells, PD-L1+ 60 
TAMs, and PD-1+ T-cells remain undefined. 
  
We used multiplex immunofluorescence and digital image analysis to examine the 
topography of PD-L1+ and PD-1+ cells in the tumor microenvironment (TME) of cHL.  We 
find that the majority of PD-L1 in the TME is expressed by the abundant PD-L1+ TAMs 65 
which physically co-localize with PD-L1+ HRS cells in a microenvironmental niche.  PD-L1+ 
TAMs are enriched for contacts with T-cells and PD-L1+ HRS cells are enriched for contacts 
with CD4+ T-cells, a subset of which  are PD-1+. Our data define a unique topology of cHL 
in which PD-L1+ TAMs surround HRS cells and implicate CD4+ T-cells as a target of PD-1 
blockade.    70 
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INTRODUCTION 
 
Classical Hodgkin Lymphoma (cHL) is a unique subtype of lymphoma, in which the 90 
malignant Hodgkin Reed-Sternberg (HRS) cells represent only a small proportion of the 
overall tumor cellularity (1-5%).1 The tumor microenvironment (TME) is predominantly 
composed of inflammatory cells, including macrophages, CD4+ and CD8+ T cells, plasma 
cells, eosinophils, and other immune cells, yet anti-tumor immunity fails to effectively 
recognize and eliminate the malignant cells.  HRS cells achieve immune evasion by multiple 95 
mechanisms including enhanced expression of programmed cell death-1 ligands (PD-L1 and 
PD-L2) that bind PD-1 (CD279) on the surface of antigen-experienced T-cells to suppress T-
cell activation, and diminished or absent expression of MHC Class I to prevent recognition 
by the adaptive immune response.2–5  
 100 
The critical role for PD-1:PD-1 ligand interactions in cHL was established with recent trials of 
monoclonal antibodies directed against PD-1.6–8 Treatment with nivolumab, a fully human 
IgG4 antibody, in a phase I study resulted in an overall response rate (ORR) of 87% and 
complete remission (CR) rate of 17% in a series of patients with multiply relapsed/refractory 
cHL.6 In an expanded phase II trial, comprising patients with relapsed/refractory disease 105 
following brentuximab vedotin and stem cell transplant, an objective response was seen in 
66.3% of patients, with a progression-free survival (PFS) at 6 months of 76.9%, including 
patients with durable remissions.  Importantly, patients with the highest PD-L1 expression 
among HRS cells had the best clinical response.7 Similar clinical response rates were found 
in trials of pembrolizumab, a distinct antibody which also targets PD-1.8,9  110 
 
PD-1 ligand expression by HRS cells is attributable, in large part, to characteristic copy 
gains of chromosome 9p24.1, which includes the PD-L1, PD-L2, and JAK2 loci, and results 
in a direct increase in PD-L1 and PD-L2 transcripts and proteins, and an indirect increase 
due to augmented JAK-STAT signaling.2,3 Critically, high level PD-L1/ PD-L2 copy gains 115 
(amplification) in HRS cells is associated with advanced stage disease and an inferior 
outcome following standard induction therapy.3  However, not all PD-L1 protein within the 
cHL TME is associated with HRS cells. We have shown that PD-L1 is also expressed by 
tumor-associated macrophages (TAMs).10 This observation is of interest, as increased TAMs 
and a macrophage-related gene expression signature predict poor clinical response to 120 
combination chemotherapy in patients with advanced stage disease.11 The number of TAMs 
that express PD-L1, the relative contribution of TAMs and HRS cells to the overall pool of 
PD-L1 in the TME, and the geographic distribution of PD-L1 expressing cells within the TME 
are undefined.  Similarly, the numbers and types of T-cells that express PD-1 and their 
geographic distribution are unknown, despite the striking clinical effectiveness of PD-1 125 
blockade.  
 
METHODS 
 
Tissue Samples 130 
Formalin-fixed, paraffin embedded (FFPE) whole tissues from tumors were derived from the 
archives of Brigham & Women’s Hospital, Boston, with IRB approval (2014P001721).  
Hematoxylin & eosin (H&E) stained tissue sections and the original diagnostic reports were 
reviewed by an expert hematopathologist (SR).  Twenty cases were selected for the study, 
based on the availability of high quality, whole lymph node excision biopsy tissue (12 EBV 135 
negative; 8 EBV positive), including nodular sclerosing (NSHL, n=11), mixed cellularity 
(MCHL, n=6), lymphocyte rich (LRCHL, n=1), and cHL, not otherwise specified (cHL, NOS, 
n=2) subtypes (Supplementary Table 1).   
 
Multiplexed Immunofluorescence (IF) 140 
Multiplexed IF was performed by staining of 4-µm thick FFPE whole tissue sections with 
standard, primary antibodies sequentially and paired with a unique fluorochrome followed by 
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staining with nuclear counterstain/ DAPI per published protocols.12–14 For example, 
deparaffinized slides were incubated with anti-PD-L1 antibody (clone 9A11, Cell Signaling 
Technology, Danvers, MA) for 40 minutes and then treated with anti-mouse horseradish 145 
peroxidase-conjugated (HRP) secondary antibody (EnVision plus, Dako, Agilent 
Technologies, Carpinteria, CA) for 30 minutes. Immunofluorescence labeling was developed 
for a strictly-observed 5 minutes using Opal-520 amplification reagent (PerkinElmer, 
Hopkinton, MA) per manufacturer’s direction. Slides were washed in Tris buffer (5 minutes) 
and then transferred to pre-heated citrate solution (90˚C), before being heat-treated using a 150 
microwave set at 20% of maximum power for 15 minutes. Slides were cooled in the same 
solution to room temperature. In between all steps, the slides were washed with Tris buffer. 
The same process was repeated for the following antibodies / fluorescent dyes, in order: 
anti-CD30 (clone BerH2, Dako) / Opal-540, anti-CD68 (clone PGM1, Dako) / Opal-650, anti-
CD163 (clone 10D6, ThermoFisher) / Opal-690.  Each slide was then treated with 2 drops of 155 
NucBlue Fixed cell ReadyProbes reagent (#P36965, Life Technologies, Carlsbad, CA), 
washed in distilled water, and manually cover-slipped. Slides were air dried, mounted with 
Prolong Diamond Anti-fade mounting medium (#P36965, Life Technologies) and stored in a 
light-proof box at 4˚C prior to imaging.  The target antigens, antibody clones, and dilutions 
for markers included in this report and details of controls are listed in Supplementary Table 2 160 
and in Supplementary Methods. 
 
Image Acquisition  
Test regions for multiplex IF analysis were identified in matched tissue sections stained for 
CD30 by chromogenic IHC. Two geographically distinct regions were selected for each 165 
tumor, to best represent the overall tissue and to include CD30+ HRS tumor cells and these 
regions were imaged using the Vectra multispectral imaging platform (Vectra 3, PerkinElmer, 
Hopkinton, MA) at 4x resolution.  Areas with non-tumor or residual normal tissue (i.e. 
residual lymph node) were excluded from the analysis. For each region, 4 tiled fields of view 
(FOVs) were acquired at 20x resolution as multispectral images. Further details are provided 170 
in Supplementary Methods.  
 
Cell Identification 
After image capture, the FOVs were spectrally unmixed and analyzed using supervised 
machine learning algorithms within Inform 2.1 (PerkinElmer), which assigns phenotypes to 175 
all cells in the image, according to a combination of immunofluorescence characteristics 
associated with segmented nuclei (DAPI signal). Each cell-phenotype specific algorithm is 
based upon an iterative training / test process, whereby a small number of cells (training 
phase, typically 15-20 cells) are manually selected as being most representative of each 
phenotype of interest and the algorithm then predicts the phenotype for all remaining cells 180 
(testing phase).12 The decisions made by the software can be over-ruled to improve 
accuracy, until phenotyping is optimized.  Unique phenotyping was performed for each 
tumor, and then applied to both tiled study images to account for inter-sample variability of 
signal intensities.  Thresholds for "positive" staining and the accuracy of phenotypic 
algorithms were confirmed by the pathologist (SR) for each case. Inform (PerkinElmer) 185 
automatically derives maps of cell membranes and Cartesian coordinates for each 
phenotyped cell within the image. 
 
Quantification of the microenvironment 
The shortest Euclidian distance from each cell of one phenotype (“A”) towards the nearest 190 
cell of a second phenotype (“B”) was calculated using the Cartesian coordinates. These 
minimum distances from each cell of type A were then averaged to calculate the average 
nearest neighbor distance between cell type A and B (NNAB).  
 
Physical interactions between two cells were determined based on the membrane maps that 195 
are provided by Inform 2.1. We examined each HRS cell, determined the numbers of each 
of the defined cell types interacting with it (i.e. CD4+ T-cells, CD8+ T-cells), and then took 
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the average result for all HRS cells.  In a similar manner, we also calculated percentages of 
populations that were within the immediate vicinity of a given cell type, e.g. the percentage 
of cell types that were not physically interacting but within a defined distance from any HRS 200 
cell. Additional details are provided in Supplementary Methods. 
 
RESULTS 
 
Cell-specific expression and localization of PD-L1+ TAMs in relation to PD-L1+ HRS cells  205 
Sequential immunofluorescence staining of 20 cases of cHL revealed the expected patterns 
of cellular staining with anti-CD30 delineating cells morphologically consistent with HRS cells, 
anti-CD68 delineating cells morphologically consistent with TAMs, and anti-PD-L1 
highlighting subsets of cells that co-express either CD30 or CD68 (Figure 1A).  The number, 
distribution and morphology of CD30+ HRS cells and CD68+TAMs observed with multiplex 210 
IF were indistinguishable from those observed with chromogenic IHC (Supplementary Figure 
1 and not shown).  A machine-learning algorithm trained on the morphological and staining 
characteristics of selected cells identified HRS cells and TAMs accurately, as judged by 
visual review, and confirmed the presence of PD-L1 positive HRS cells and TAMs in every 
case tested (Figure 1B).  We quantified the relative contribution of HRS cells and TAMs to 215 
total PD-L1 staining (calculated as percentage of total fluorescence units), and found that, 
for every case, TAMs contributed the majority of PD-L1 in the tumor microenvironment 
(TME) (Figure 1B).  A mean of 78.5% of the total PD-L1 expression within the TME was 
contributed by TAMs across the series (range 50.4 – 98.5%; S.D. = 14.8). 
 220 
Visual inspection of stained tissue sections suggested possible enrichment of PD-L1+ TAMs 
in the vicinity of PD-L1+ HRS cells (exemplified by case P6, Figure 2A; Supplementary 
Figure 2).  To quantify this observation, we used the Cartesian coordinates for each of the 
thousands of cells of interest within each tissue section (Figure 2B), and calculated the 
respective distances from each PD-L1+ TAM to the nearest PD-L1+ HRS cell (Figure 2C) 225 
and the distances from each PD-L1- TAM to the nearest PD-L1+ HRS cell (Figure 2D). In all 
20 cases, the mean distance from PD-L1+ TAMs to the nearest PD-L1+ HRS cell was 
significantly less than the mean distance from PD-L1- TAMs to the nearest PD-L1+ HRS cell 
(Figure 2E).  This difference was highly significant across the case series (p< 0.0001, paired 
t-test).  Conversely, the mean distance from PD-L1+ HRS cells to PD-L1+ TAMs was shorter 230 
than the mean distance from PD-L1+ HRS cells to PD-L1- TAMs in 18 of 20 cases 
(Supplementary Figure 2G).  This difference was also highly significant across the case 
series (p=0.0002, paired t-test).  
 
To ensure the specificity of the analysis, we also optimized IF staining for CD163, a 235 
macrophage marker with a more restricted expression pattern than CD68 (Supplementary 
Figure 3).  We found that the majority of cells with positive staining for CD68 were also 
positive for CD163, as expected (Supplementary Figure 4A-D).  By quantitative analysis, we 
found that the mean distance from PD-L1+ CD68+ CD163+ TAMs to the nearest PD-L1+ 
HRS cell was significantly less than the mean distance from PD-L1- CD68+ CD163+ TAMs 240 
to the nearest PD-L1+ HRS cell in all cases (p < 0.0001, paired t-test; Supplementary Figure 
4E); consistent with coordinate localization of PD-L1+ TAMs with PD-L1+ HRS cells.  
  
T-cell specific expression and localization of PD-1  
Immunostaining for PD-1 revealed positive staining of a subset of lymphocytes in cHL 245 
(Supplementary Figure 5).  Quantitative analysis confirmed that PD-1+ cells accounted for a 
minority of the T-cell population across the series (median 9% of CD4+ T-cells and 18% of 
CD8+ T-cells).  In addition, we observed that levels of cellular PD-1 expression were lower 
among positive staining lymphocytes in the vicinity of HRS cells compared to positive 
staining lymphocytes within the residual germinal centers that were found in a subset of 250 
cases (Supplementary Figure 5).  Quantitative analysis confirmed that the mean PD-1 
expression by positive staining CD3+ T-cells in the vicinity of HRS cells was lower than 
For personal use only.on September 19, 2017. by guest  www.bloodjournal.orgFrom 
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among the PD-1high follicular helper T-cells (TFH) within reactive germinal centers; consistent 
with the notion that PD-1+ T-cells in the cHL TME express PD-1 at low to intermediate levels 
(Supplementary Figure 5E).15,16  255 
 
PD-1+ T-cells in relation to PD-L1+ TAMs 
Visual inspection and cell phenotyping revealed that a subset of PD-1+ cells within the cHL 
TME are CD4+ and that these cells appeared enriched in the vicinity of PD-L1+ TAMs 
(exemplified by case N10, Figure 3A; B).  Quantitative analysis revealed that the mean 260 
distance from PD-1+ CD4+ T-cells to the nearest PD-L1+ TAM was less than the mean 
distance from PD-1+ CD4+ T-cells to the nearest PD-L1- TAM in 16 of 20 cases (Figure 3C).  
This difference in distances was highly significant across the case series (p=0.004; Figure 
3C).  Similarly, we observed that the mean distance from PD-1+ CD8+ T-cells to the nearest 
PD-L1+ TAM (exemplified by case P6, Figure 3D; E) was less than the mean distance from 265 
PD-1+ CD8+ T-cells to the nearest PD-L1- TAM in 15 of 20 cases (Figure 3F). This 
difference was highly significant for the series (p=0.005) and, overall, consistent with 
coordinate regional localization of PD-1+ T-cells and PD-L1+ TAMs.  The mean distance 
from PD-1+ T-cells to PD-L1+ TAMs was also weakly, but positively correlated with  the 
mean distance from PD-L1+ TAMs to PD-L1+ HRS cells for the series (r=0.269 for CD4+ T-270 
cells and r=0.283 for CD8+ T-cells, respectively).  
 
PD-1+ T-cells in relation to PD-L1+ HRS cells 
We further wished to determine whether PD-1+ T-cells were preferentially oriented in 
proximity to PD-L1+ HRS cells.  Quantitative analysis revealed that the mean distance from 275 
PD-1+ CD4+ T-cells to the nearest PD-L1+ HRS cell was less than the mean distance from 
PD-1+ CD4+ T-cells to the nearest PD-L1- HRS cell in 15 of 20 cases (Supplementary 
Figure 6).  Thie difference was significant across the case series (p=0.03; Supplementary 
Figure 6C).  The mean distance from PD-1+ CD8+ T-cells to the nearest PD-L1+ HRS cell 
(exemplified by case P6, Supplementary Figure 6D; E) was less than the mean distance 280 
from PD-1+ CD8+ T-cells to the nearest PD-L1- HRS cell in 13 of 20 cases (Supplementary 
Figure 6F).  The difference did not reach significance for the series (p=0.1). 
 
T-cells in direct contact with TAMs 
Close visual inspection of stained tissue sections indicated PD-1+ expression on a subset of 285 
CD4+ T-cells and a subset of CD8+ T-cells in direct contact with TAMs (Figure 4A-D).  CD4+ 
T-cells were more likely than CD8+ T-cells to be in direct contact with TAMs across the 
series (28% [95% CI 22%-34%] versus 7% [95% CI 6%-9%], respectively, Figure 4E).  
Moreover, CD4+ T-cells and CD8+ T-cells, as proportions of the cellularity, were both 
significantly higher at the points of contact with TAMs than at points without contact (>75 µm 290 
distant; p =0.01 and < 0.01, respectively; Figure 4E).  
 
PD-1+ CD4+ T-cells also exceeded PD-1+ CD8+ T-cells in contact with PD-L1+ TAMs 
across the series (3.9% [95% CI 1.6%-6.3%] versus 1.8% [95% CI 1.0%-2.7%], respectively).   
Like T-cells in general, PD-1+ CD4+ T-cells and PD-1+ CD8+ T-cells, as proportions of the 295 
cellularity, were significantly higher at the points of contact with PD-L1+ TAMs than at points 
without contact (>75 µm distant; p= 0.04 and <0.01, respectively; Figure 4F) consistent with 
the notion that PD-1+ CD4+ T-cells and PD-1+ CD8+ T-cells in contact with PD-L1+ TAMs 
are a locally enriched population.   
 300 
T-cells in direct contact with HRS cells 
We also observed PD-1 on subsets of CD4+ T-cells and CD8+ T-cells in direct contact with 
HRS cells (Figure 5A-D). CD4+ T-cells exceeded CD8+ T-cells in contact with HRS cells 
across the series (35% of all contacts [95% CI 28%-42%] versus 4% all contacts [95% CI 
3%–6%], respectively, Figure 5E).  CD4+ T-cells, as proportions of the cellularity, were 305 
significantly higher at the points of contact with HRS cells than at points without contact (p 
<0.01; Figure 5E).  In contrast, CD8+ T-cells, as proportions of the cellularity, were not 
For personal use only.on September 19, 2017. by guest  www.bloodjournal.orgFrom 
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significantly different at the points of contact with HRS cells and at points without contact (p= 
0.78; Figure 5E). 
 310 
When the PD-1 status of the T-cells and PD-L1 status of the HRS cells were considered, we 
found that PD-1+ CD4+ T-cells exceeded PD-1+ CD8+ T-cells in contact with PD-L1+ HRS 
cells (4.7% of all contacts [95% CI 2.3%-7.1%] versus 1.8% [95% CI 0.8%-2.8%] 
respectively, Figure 5F).  Like CD4+ T-cells in general, PD-1+ CD4+ T-cells were a higher 
proportion of the cellularity at the points of contact with PD-L1+ HRS than at points without 315 
contact (p< 0.01; Figure 5F).  In contrast, the proportion of PD-1+ CD8+ T-cells was not 
significantly different between the points of contact with PD-L1+ HRS cells and at points 
without contact (p= 0.37; Figure 5F), consistent with the notion that PD-1+ CD4+ T-cells, but 
not PD-1+ CD8+ T-cells, are enriched in immediate proximity to PD-L1+ HRS cells. 
 320 
DISCUSSION 
 
PD-1 blockade is especially effective in cHL, where 65-85% of patients with 
relapsed/refractory disease demonstrate clinical response.6–8 The sensitivity of cHL to PD-1 
blockade is determined, in part, by genetic gains of PD-L1 and PD-L2 within the malignant 325 
HRS cells that result in robust expression of the PD-1 ligands that, in turn, engage PD-1 on 
infiltrating immune cells.2,3,10,17 Here in, we defined the expression and topographic 
distribution of PD-L1+ and PD-1+ non-malignant cells in the cHL microenvironment.  We 
characterized the complex cellular TME in cHL using FFPE diagnostic biopsies, 
simultaneously identifying tens of thousands of cells per sample across large regions of 330 
interest, including malignant HRS cells, TAMs and T-cells. In addition, we developed and 
employed the analytic means to quantify the relative proportion and location of cells 
expressing PD-L1 and PD-1, and the spatial relationships between specific cell populations.   
 
By these methods, we detected PD-L1 expression by at least a subset of HRS cells and 335 
TAMs in all cHLs, as in our previous studies using chromogenic IHC.10  In all tumors, the 
majority of tissue PD-L1 was expressed by TAMs.  This result is consistent with the 
observation that TAMs are, in general, far more common than HRS cells.  Moreover, we find 
that TAMs are not randomly distributed; instead PD-L1+ TAMs lie in greater proximity to PD-
L1+ HRS cells than PD-L1- TAMs.  The biological importance of this microenvironmental 340 
niche is supported by the preferential localization of PD-1+ T-cells in proximity to and for 
contact with PD-L1+ TAMs.  Taken together, our results suggest a model in which the 
inflammatory microenvironment of cHL is highly organized with PD-L1+ TAMs immediately 
surrounding HRS cells to engage PD-1+ T-cells and augment immunosuppression 
 (Figure 6).  345 
 
Whether PD-L1 expression by TAMs is directly dependent upon the presence of HRS cells 
is unknown, but the PD-L1+ TAMs are likely programmed as a consequence of the local 
cytokine milieu.  Macrophages demonstrate marked phenotypic plasticity in response to their 
environment,18  and the induction of PD-L1 can be mediated by a variety of cytokines, 350 
including IFNγ and GM-CSF.17,19,20 These, and other pro-inflammatory cytokines, are 
produced by HRS cells, but also the T-cells, natural killer (NK) cells, and myeloid cells within 
the TME.19,21 In this respect, the inflammatory TME of cHL resembles that of certain solid 
tumors, in which PD-L1 expression by non-malignant cells, including macrophages, is 
prominent.22  It will be of interest to micro-dissect and to interrogate regions rich in PD-L1+ 355 
TAMs to characterize the spectrum of cytokines and chemokines that define this specialized 
niche in greater detail.  It will also be of interest to specifically isolate PD-L1+ TAMs to 
determine whether they express additional phenotypic markers of immunosuppression, such 
as indoleamine 2,3-dioxygenase 1 (IDO1), which might be targetable and thus synergize 
with PD-1 blockade.18,23   360 
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To be effective, PD-L1 must engage PD-1 to inhibit anti-tumor immunity.  Despite the 
marked clinical efficacy of checkpoint blockade, the critical cell populations that express PD-
1 and effect anti-tumor immunity in cHL have remained undefined.  We examined the 
expression of PD-1 on T-cells and found that those within the TME of cHL express PD-1 at 365 
intermediate levels.  Prior studies have established that T-cells with intermediate or low 
levels of PD-1 expression are antigen-experienced, “exhausted” T-cells that are primed for 
reactivation, whereas those with the highest levels of PD-1 include TFH cells in germinal 
centers and T-cells with an irreversibly “exhausted” phenotype in the periphery.15,16,24 Thus, 
our data suggest that the majority of PD-1+ T-cells within the TME of cHL have a PD-1 370 
phenotype primed for re-activation.   
 
CD4+ and CD8+ T-cells, including a subset that are PD-1+, are enriched in the vicinity of, 
and in contact with, PD-L1+ TAMs.  This observation is consistent with the role of TAMs as 
professional antigen presenting cells (APCs) that process and present exogenous antigens, 375 
including those potentially from HRS cells, to CD4+ T-cells by the MHC Class II pathway and, 
through cross-presentation, to CD8+ T-cells by the MHC Class I pathway.18  As a 
consequence, the PD-L1+ TAMs may both promote anti-tumor immunity through antigen 
presentation to T-cells and to immunosuppression through the engagement of PD-1.  
Validation of these proposed activities will require functional studies.    380 
 
We find that CD4+ T-cells are more often in contact with HRS cells than CD8+ T-cells, 
consistent with previous studies.25   Moreover, CD4+ T-cells in contact with HRS cells 
represent a locally enriched population, whereas CD8+ T-cells do not.  Regions with HRS 
cells can be locally dense in inflammatory cells, a characteristic that can impact spatial 385 
analysis.  This is particularly true in the nodular sclerosis subtype compared to the mixed 
cellularity subtype of cHL.  Regardless of subtype, however, we find that PD-L1+ 
macrophages and CD4+ T-cells are enriched relative to PD-L1- macrophages and CD8+ T-
cells in the vicinity of and for contact with HRS cells. 
 390 
Similarly, we find that PD-1+ CD4+ T-cells but not PD-1+ CD8+ T-cells in contact with PD-
L1+ HRS cells represent a locally enriched population.  These observations are of particular 
interest given that HRS cells more generally express MHC class II than MHC class I.4,26   
Inactivating somatic mutations in β2-microglobulin (β2M) is a frequent genetic lesion among 
HRS cells, and the reduction and loss of  expression of the β2M / MHC class I complex might 395 
be expected to compromise the ability of HRS cells to engage CD8+ T-cells.4,5,26  The high 
percentage of cHLs with reduction or complete loss of the β2M/ MHC class I protein complex 
(79%) also indicates that CD8+ T-cells are unlikely to be the only effector cells associated 
with the efficiency of PD-1 blockade (65-85%) in cHL.4 
 400 
Indeed, our data suggest that PD-1+ CD4+ T-cells may play a more important role in the 
anti-tumor response than previously anticipated.  Recent studies indicate that CD4+ T-cells 
may themselves be able to directly kill tumor cells (even those lacking MHC-II), using 
mechanisms that are more traditionally associated with CD8+ CTLs.27,28  In subsequent 
studies, it will be important to employ additional phenotypic markers to further define the PD-405 
1+ CD4+ T-cell population, including those that identify CD4+ cytotoxic T-cells, Th1-type and 
Th2-type T-cells, and T-regulatory cells.29  It will be useful to determine whether these cells 
express additional immunoregulatory proteins, such as LAG-3, which are also targetable 
with novel therapies.30 These data also suggest the importance of determining the 
distribution and extended functional phenotypes of additional cell lineages, such as NK cells, 410 
NK/T-cells, and γδ T-cells, which can have prominent roles in executing anti-tumor immunity 
in the absence of MHC class I.31,32 The methods described in this study can also be applied 
to B-cells, plasma cells, and other components of humoral immunity.  
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Finally, the systematic analysis of a large cohort of diagnostic biopsy specimens, preferably 415 
in the context of a clinical trial, will be necessary to determine whether the topological 
arrangements we observe are associated with response to therapy.  In addition, it will be 
essential to analyze biopsy samples taken from patients while on PD-1 inhibitor therapy to 
positively identify cell populations that are primarily responsible for HRS cell killing. 
 420 
In summary, we have quantified PD-L1:PD-1 interactions in a series of cHL and find a 
common architectural framework in which the majority of PD-L1 in the microenvironment is 
derived from TAMs which, like HRS cells, are in extensive contact with PD-1+ T-cells. We 
propose that HRS tumor cells survive within a specialized cellular niche, an even more 
localized microenvironment within the broader tumor mass.  This expands the overall pool of 425 
available PD-L1 surrounding HRS cells, and increases the potential for functional 
downregulation of PD-1+ T-cells before or at the time that they interact with HRS cells.  
Given that PD-L1+ and PD-1+ cells are in immediate proximity and in contact with HRS cells, 
it appears that the immune-suppressive and immune-stimulatory mechanisms governing 
anti-tumor immunity exist in a delicate and dynamic equilibrium.  Further defining this 430 
immunologically privileged niche may uncover additional therapeutic targets.   
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FIGURE LEGENDS 
 545 
 
Figure 1.  
 
Expression of PD-L1 by HRS cells and TAMs. (A) Multiplex immunofluorescence staining 
(40x resolution, case P6) for CD30 (top left, orange) to highlight HRS cells, CD68 (bottom 550 
left, magenta) to highlight TAMs, and PD-L1 (green) to show co-localization of PD-L1 and 
CD30 (top right, co-localization= yellow) and PD-L1 and CD68 (bottom right).  Each image 
includes a nuclear counterstain/DAPI (blue).  (B) The relative amount of total PD-L1 per 
tumor (calculated as percentage of total fluorescence units), contributed by HRS cells 
(black) and TAMs (gray). The cases are ordered by the percentage of PD-L1 attributed to 555 
HRS cells, from highest to lowest. Cell lineage assignments (HRS cell; TAM) are based 
upon pathologist-trained algorithms and include data from all fluorescent-channels (see 
Methods). 
 
Figure 2.  560 
 
Distances from PD-L1+ TAMs and PD-L1- TAMs to the nearest PD-L1+ HRS cells.  
(A) Representative multiplex IF image (20x resolution; case P6) showing staining for CD30 
(orange), CD68 (magenta), and PD-L1 (green).  (B) Cellular phenotype map of the image 
shown in (A) depicting locations of PD-L1+ HRS cells (orange dots), PD-L1+ TAMs (purple 565 
dots), and PD-L1- TAMs (pink dots).  (C) Ray plot depicting the distance from each PD-L1+ 
TAM to the nearest PD-L1+ HRS cell.  (D) Ray plot depicting the distance from each PD-L1- 
TAM to the nearest PD-L1+ HRS cell.  (E) The mean distances (microns) and standard 
errors for all 20 study tumors, divided into ‘mean distance from PD-L1- TAMs to the nearest 
PD-L1+ HRS cells’ (gray) and ‘mean distance from PD-L1+ TAMs to the nearest PD-L1+ 570 
HRS cells’ (black). The tumors are ordered by the distances from PD-L1- TAMs to PD-L1+ 
HRS cells, from highest to lowest; p value (<0.0001) was calculated by paired t-test.  NN= 
nearest neighbor.  
 
Figure 3.  575 
 
Distances from PD-1+ CD4+ and PD-1+ CD8+ T-cells to the nearest PD-L1+ TAMs.  (A) 
Representative multiplex IF image (20x resolution; case N10) showing staining for CD4 
(cyan), PD-1 (yellow), CD68 (magenta), and PD-L1 (green). (B) Cellular phenotype map of 
image shown in (A) depicting the locations of PD-1+ CD4+ T-cells (green dots), PD-L1+ 580 
TAMs (purple dots), PD-L1- TAMs (pink dots), and undefined cells (gray dots).  (C) The 
mean distances (microns) and standard errors for all 20 study tumors, divided into ‘mean 
distance from PD-1+ CD4+ T-cells to the nearest PD-L1+ TAMs’ (black) and ‘mean distance 
from PD-1+ CD4+T-cells to the nearest PD-L1- TAMs’ (gray). Tumors are ordered by the 
distance between PD-1+ CD4+ T-cells and PD-L1- TAMs, from highest to lowest; p value 585 
(0.004) was calculated by paired t-test. (D) Representative multiplex IF image (20x 
resolution; case P6) showing staining for CD8 (red), PD-1 (yellow), CD68 (magenta), and 
PD-L1 (green).  (E) Cellular phenotype map of image shown in (D) depicting the locations of 
PD-1+ CD8+ T-cells (red dots), PD-L1+ TAMs (purple dots), PD-L1- TAMs (pink dots), and 
undefined cells (gray dots).  (F) The mean distances (microns) and standard error for all 20 590 
study tumors, divided into ‘mean distance from PD-1+ CD8+ T-cells to the nearest PD-L1+ 
TAMs’ (black) and ‘mean distance from PD-1+ CD8+ T-cells to the nearest PD-L1- TAMs’ 
(gray). Tumors are ordered by the distance from PD-1+ CD8+ T-cells to the nearest and PD-
L1- TAMs, from highest to lowest; p value (0.005) was calculated by paired t-test.  NN= 
nearest neighbor. 595 
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Figure 4.  
 600 
T-cell subsets in contact with TAMs.  (A) Representative image (40x resolution; case 
N13) showing CD4+ T-cells (left panel, green) with co-expression of PD-1 (right panel, 
yellow) touching CD68+ TAMs (left and right panels, magenta). (B) Membrane map 
depicting CD4+ T-cells (PD-1+ dark green; PD-1- light green), and PD-L1+ TAMs (purple). 
Cells are generally only outlined, with the exceptions of PD-1+ CD4+ T-cells and PD-L1+ 605 
TAMs that are in contact, which are filled to highlight the interaction. (C) Representative 
image (40x resolution; case N13) showing CD8+ T-cells (left panel, red) with co-expression 
of PD-1 (right panel, yellow) touching CD68+ TAMs (left and right panels, magenta).  (D) 
Membrane map depicting CD8+ T-cells (PD-1+ dark red; PD-1- light red), and PD-L1+ TAMs 
(purple). Cells are generally only outlined, with the exceptions of PD-1+ CD8+ T-cells and 610 
PD-L1+ TAMs that are in contact, which are filled. (E) Mean and standard error of the 
proportion of cells that are CD4+ T-cells, CD8+ T-cells or undefined that are in contact with 
TAMs (black bars), within 75 µm of TAMs (gray bars), or >75 µm from TAMs (light gray bars), 
respectively; p values calculated by the Wilcoxon test.  (F) Mean and standard error of the 
proportion of cells that are PD-1+ CD4+ T-cells, PD-1- CD4+ T-cells, PD-1+ CD8+ T-cells, or 615 
PD-1- CD8+ T-cells and that are in contact with PD-L1+ TAMs (black bars), within 75 µm of  
PD-L1+TAMs (gray bars), or >75 µm from PD-L1+ TAMs (light gray bars), respectively; p 
values calculated by the Wilcoxon test.   
 
Figure 5.  620 
 
T-cell subsets in contact with HRS cells.  (A) Representative image (40x resolution; case 
N12) showing CD4+ T-cells (left panel, green) with co-expression of PD-1 (right panel, 
yellow) touching a CD30+ HRS cell (left and right panels, orange). (B) Membrane map 
depicting CD4+ T-cells (PD-1+ dark green; PD-1- light green), and PD-L1+ HRS cells 625 
(orange). Cell are generally only outlined, with the exceptions of PD-1+ CD4+ T-cells and 
PD-L1+ HRS cells that are in contact, which are filled to highlight the interaction.  (C) 
Representative image (40x resolution; case P6) showing CD8+ T-cells (left panel, red) with 
co-expression of PD-1 (right panel, yellow) touching CD30+ HRS cells (left and right panels, 
orange).  (D) Membrane map depicting CD8+ T-cells (PD-1+ dark red; PD-1- light red), and 630 
PD-L1+ HRS cells (orange). Cell are generally only outlined, with the exceptions of PD-1+ 
CD8+ T-cells and PD-L1+ HRS cells that are in contact, which are filled. (E) Mean and 
standard error of the proportion of cells that are CD4+ T-cells, CD8+ T-cells or undefined 
and that are in contact with HRS cells (black bars), within 75 µm of HRS cells (gray bars), or 
>75 µm from the HRS cells (light gray bars), respectively; p values calculated by the 635 
Wilcoxon test.  (F) Mean and standard error of the proportion of cells that are PD-1+ CD4+ 
T-cells, PD-1- CD4+ T-cells, PD-1+ CD8+ T-cells, or PD-1- CD8+ T-cells in contact with PD-
L1+ HRS cells (black bars), within 75 µm of PD-L1+ HRS cells (gray bars), or >75 µm from 
PD-L1+ HRS cells (light gray bars), respectively; p values calculated by the Wilcoxon test. 
 640 
Figure 6. 
 
Model of PD-1:PD-L1 Interactions in cHL.  Hodgkin Reed-Sternberg cells (purple) express 
PD-L1 (and PD-L2) due, in part, to copy gain of chromosome 9p24.1 which includes PD-
L1/PD-L2/JAK2.  Tumor-associated macrophages (blue) that are in proximity to HRS cells 645 
express high levels of PD-L1, likely in response to local cytokine production, and thereby 
significantly increase the total amount of PD-L1 in the vicinity of the malignant cells.  Both 
TAMs' and HRS cells' PD-L1 is available to bind PD-1 on CD4+ T-cells (green) and CD8+ T-
cells (red). CD4+ T-cells and PD-1+ CD4+ T-cells are in greater numbers and are 
specifically enriched in the vicinity of PD-L1+ HRS cells compared to CD8+ T-cells and PD-650 
1+ CD8+ T-cells and may indicate a preferential role for CD4+ T-cells during PD-1 blockade. 
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